He was awarded a prestigious fellowship in 2010 by Arthritis Research UK to perform diagnostics research in the University of Colorado, Denver, USA. He holds a PhD from Queen’s University Belfast, awarded in 2001 for work on drugs to reduce spread of brain cancers.
In his role as Chief Scientific Officer he oversees the translation of lab based research, via rigorous clinical trials, to novel treatments for a wide range of chronic conditions. His personal research focus with GreenLight Medicines is to identify phytocannabinoids which reduce pain and inflammatory signalling most effectively, in collaboration with Ulster University.
Le Roy obtained a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University (2002). After a period of post-doctoral research, he became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy set up the BMSRI Core Facility Units to support academic and commercial research, and since 2012 he has worked with colleagues to bring over £17.5m of research and innovation funding into the University and NI. In 2015 he was appointed Commercial Manager at C-TRIC (Clinical Translational Research Innovation Centre) where he worked closely with the Western Health and Social Care Trust, Ulster University, Derry City & Strabane District Council, North West Regional College, lnvestNI and local companies, to develop economic growth and supply bio-businesses with support and advice. Le Roy returned to Ulster as BMSRI’s Business Development Manager, managing the Core Facility Units and an expert team of Scientific Assistants/Officers.
Le Roy joined the GreenLight Team in June 2018 as Director of Corporate Development, and is now Chief Operating Officer.
He is extremely passionate about investigating avenues that chronic conditions can be treated by holistic and natural methods. He has a strong interest in epigenetic factors that influence mental health conditions such as anxiety and depression. Dr. Daly is dedicated to the pursuit of human longevity and bringing the latest research on nutrition and disease prevention to the population.
Prof. Cotter is also co-founder of two start-up biotechnology companies. One of which was London (AIM) listed and the second bought outright by a US multinational in 2018. He was a founding board member of Science Foundation Ireland (Irelands largest science funding body), and served on the board of The Health Research Board of Ireland. He is also a past member of the SAB of The Tyndall National Institute and several small companies. He is currently on the SAB of The Institute de la Vision Paris, one of the world’s top research centres for vision research. He has extensive experience at reviewing research applications, both academic and industry at an international level.
Prof Cotter research interests cover cell signalling and therapeutic strategies in oncology and degenerative conditions of the retina. He is the author of 250 publications and the editor of several books.
Professor Murphy has over 240 international publications, most recently in models of dependence, addiction and demyelination. He was awarded the Rafaelsen Scholarship, CINP Young Investigator award, 25th Congress of the Collegium Internationale Neuro-psychopharmacologicum, Chicago.
He has published over 200 articles within the field of rheumatology, most recently on genetic and epigenetic markers of disease susceptibility and drug response in rheumatoid arthritis.